Affiliation:
1. Keck School of Medicine, University of Southern California, Los Angeles, California, USA;
2. Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA;
3. Division of Gastroenterology and Liver Diseases, University of Southern California, Los Angeles, California, USA.
Abstract
INTRODUCTION:
The National Institute on Minority Health and Health Disparities has noted that transgender individuals experience unique health disparities. We sought to describe the landscape of transgender patients with cirrhosis.
METHODS:
We identified all transgender and cisgender adults in Optum's deidentified Clinformatics Data Mart Database between 2007 and 2022 using validated billing codes and calculating age-standardized prevalence of cirrhosis among cisgender vs transgender adults. Among those with incident cirrhosis diagnoses, we calculated age-standardized incidence densities of liver-related outcomes (decompensation, transplantation, hepatocellular carcinoma) and all-cause mortality. We examined 5-year survival using inverse probability treatment weighting to balance transgender and cisgender populations on demographic and clinical characteristics.
RESULTS:
Among 64,615,316 adults, 42,471 (0.07%) were transgender. Among 329,251 adults with cirrhosis, 293 (0.09%) were transgender. Trans- (vs cis-) genders had higher prevalence of cirrhosis (1,285 [95% confidence interval (CI) 1,136–1,449] per 100,000 vs 561 [559–563] per 100,000). Among adults with cirrhosis, trans- (vs cis-) genders had higher proportions of anxiety (70.7% [56.9–86.9] vs 43.2% [42.7–43.8]), depression (66.4% [53.3–81.7] vs 38.4% [37.9–38.9]), HIV/AIDS (8.5% [3.9–16.1] vs 1.6% [1.5–1.7]), and alcohol (57.5% [46.0–71.1] vs 51.0% [50.5–51.6]) and viral (30.5% [22.8–39.8] vs 24.2% [23.9–24.5]) etiologies, although etiologies had overlapping CIs. Trans- (vs cis-) genders had similar incidence densities of death (12.0 [95% CI 8.8–15.3] vs 14.0 [13.9–14.2] per 100 person-years), decompensation (15.7 [10.9–20.5] vs 14.1 [14.0–14.3]), and liver transplantation (0.3 [0.0–0.8] vs 0.3 [0.3–0.4]). In inverse probability treatment weighting survival analysis, transgender and cisgender individuals had similar 5-year survival probabilities (63.4% [56.6–71.1] vs 59.1% [58.7–59.4]).
DISCUSSION:
Trans- (vs cis-) gender adults have double the prevalence of cirrhosis, and the majority have a diagnosis of anxiety and/or depression. These results are informative for researchers, policymakers, and clinicians to advance equitable care for transgender individuals.
Funder
National Institute on Alcohol Abuse and Alcoholism
the USC Research Center for Liver Diseases
Publisher
Ovid Technologies (Wolters Kluwer Health)